Sorry, you need to enable JavaScript to visit this website.

VYNDAQEL® OR VYNDAMAX™ (tafamidis meglumine or tafamidis) Indications and Usage

1. INDICATIONS AND USAGE

VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

What's New

No Current Announcements.

Contact Pfizer Medical

Report an Adverse Event
1-800-438-1985

Search

Please enter your search term(s) for VYNDAQEL® OR VYNDAMAX™